- Conditions
- Pancreatic Ductal Carcinoma
- Interventions
- Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), Placebo, nab-Paclitaxel, Gemcitabine
- Other · Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 492 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 64
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced May 22, 2026, 5:52 AM EDT